Search Results 501-510 of 18363 for alopecia
... alopecia * Known clinically active human immunodeficiency virus, active hepatitis B or active hepatitis C infection * For newly diagnosed cohorts: received ...
alopecia and stable neuropathy, which must have resolved to Grade ≤ 2 or baseline. 10. Radiotherapy, including palliative radiotherapy, completed at least ...
* Unresolved or neuroendocrine histology, nor sarcomatoid features adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.
... alopecia) have not been recovered. 20. Patients who are taking anticoagulant therapy (prophylactic use of low-dose aspirin \[≤ 100 mg/day\] or low ...
... alopecia, and irreversible late sequelae of radiation therapy, must have resolved to Grade 0 or 1 per Common Terminology Criteria for Adverse Events (CTCAE ...
... alopecia, anemia and any signs or symptoms of androgen deprivation therapy; Must be willing to not add, delete or change their current bisphosphonate or ...
... alopecia in breast cancer. Support Care Cancer. 2024 Jun 6; 32 (7):412 Epub 2024 June 06. View PubMed; Haemmerle R, Paludo J, Haddad TC, Pritchett JC. The ...
Patients with well-controlled hyper/hypothyroidism, celiac controlled by diet alone, diverticulosis, diabetes mellitus type I, vitiligo, alopecia, psoriasis ...
0, except for alopecia. Patients with chronic but stable Grade 2 toxicities may be allowed to enroll after an agreement between the Investigator and Sponsor ...
NOTE: All residual toxicities (except alopecia) should be at baseline or grade 1 (including peripheral neuropathy). NOTE: If indicated, patients can ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!